- Trials with a EudraCT protocol (25)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
25 result(s) found for: Human pathogen.
Displaying page 1 of 2.
EudraCT Number: 2011-003895-35 | Sponsor Protocol Number: D4280C00005 | Start Date*: 2012-04-11 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole V... | |||||||||||||
Medical condition: Complicated Intra-Abdominal Infection (cIAI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) CZ (Completed) GR (Completed) ES (Completed) BG (Completed) IT (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002314-39 | Sponsor Protocol Number: Semaglutide2019 | Start Date*: 2021-07-08 | ||||||||||||||||
Sponsor Name:University College Dublin (UCD) | ||||||||||||||||||
Full Title: A randomised, controlled, parallel group, open-label trial evaluating the impact of treatment with the GLP-1 analogue semaglutide on weight loss in people living with HIV and obesity | ||||||||||||||||||
Medical condition: Human immunodeficiency virus (HIV) Infection and Obesity | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000211-25 | Sponsor Protocol Number: MV-CHIK-205 | Start Date*: 2018-07-27 |
Sponsor Name:Themis Bioscience GmbH | ||
Full Title: Observer blinded, randomised study to investigate safety, tolerability and long-term immunogenicity of different dose regimens and formulations of MV-CHIK in healthy volunteers | ||
Medical condition: The study is being conducted in healthy volunteers for the prophylaxis of chikungunya virus (CHIKV) infection. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-005003-33 | Sponsor Protocol Number: WSA-CS-003 | Start Date*: 2008-06-26 | |||||||||||
Sponsor Name:Astellas Global Pharma Development, Inc | |||||||||||||
Full Title: Open label study of isavuconazole in the treatment of patients with aspergillosis and renal impairment or of patients with invasive fungal disease caused by rare moulds, yeasts or dimorphic fungi. | |||||||||||||
Medical condition: Invasive fungal disease caused by Aspergillus species in patients with renal impairment as well as disease caused by rare moulds, yeasts or dimorphic fungi. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) HU (Completed) CZ (Prematurely Ended) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001609-89 | Sponsor Protocol Number: DORI-10 | Start Date*: 2005-04-26 |
Sponsor Name:Peninsula Pharmaceuticals, Inc | ||
Full Title: A Multicenter, Randomized, Open-Label Phase 3 Study to Compare the Safety and Efficacy of Intravenous Doripenem with that of Intravenous Imipenem in Ventilator-Associated Pneumonia | ||
Medical condition: patients diagnosed with ventilator-associated pneumonia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) EE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003644-23 | Sponsor Protocol Number: PTK0796-ABSI-1108 | Start Date*: 2015-07-02 | |||||||||||
Sponsor Name:Paratek Pharma LLC | |||||||||||||
Full Title: A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adult Subjects with Acute Bacterial Skin and Skin Str... | |||||||||||||
Medical condition: Acute Bacterial Skin and Skin Structure Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) HU (Completed) ES (Completed) PL (Completed) GR (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001117-42 | Sponsor Protocol Number: DORI-NOS-2001 | Start Date*: 2007-10-18 | ||||||||||||||||
Sponsor Name:Janssen Cilag International NV | ||||||||||||||||||
Full Title: A Randomized, Open-Label, Multicenter Study to Assess the Safety and Tolerability of Doripenem Compared With Imipenem in the Treatment of Subjects With Complicated Intra-Abdominal Infections or Ven... | ||||||||||||||||||
Medical condition: ventilator-associated pneumonia complicated intra-abdominal infections | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002669-45 | Sponsor Protocol Number: ICL-23-ABSSSI1 | Start Date*: 2016-02-18 | |||||||||||
Sponsor Name:Motif BioSciences Inc. | |||||||||||||
Full Title: A Phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim versus vancomycin in the treatment of acute bacterial skin and skin structure infe... | |||||||||||||
Medical condition: Acute bacterial skin and skin structure infections (ABSSSIs) suspected or confirmed to be due to Gram-positive pathogens. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) DE (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002687-16 | Sponsor Protocol Number: ICL-24-ABSSSI2 | Start Date*: 2016-05-05 | |||||||||||
Sponsor Name:Motif BioSciences Inc. | |||||||||||||
Full Title: A Phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim versus vancomycin in the treatment of acute bacterial skin and skin structure infe... | |||||||||||||
Medical condition: Acute bacterial skin and skin structure infections (ABSSSIs) suspected or confirmed to be due to Gram-positive pathogens. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BE (Completed) HU (Completed) PT (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001696-22 | Sponsor Protocol Number: 64041575MPN2001 | Start Date*: 2018-06-28 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine ... | |||||||||||||
Medical condition: Human metapneumovirus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Temporarily Halted) PL (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001832-27 | Sponsor Protocol Number: AT-202 | Start Date*: 2023-01-20 | ||||||||||||||||
Sponsor Name:Allecra Therapeutics SAS | ||||||||||||||||||
Full Title: A Single Group Treatment, Phase 2 study to investigate Pharmacokinetics, Safety and Tolerability of Cefepime-Enmetazobactam administered by intra-venous infusion over 2 hours in Male or Female Part... | ||||||||||||||||||
Medical condition: Complicated urinary tract infections including acute pyelonephritis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) SK (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003630-18 | Sponsor Protocol Number: ICLA-09-CSI2 | Start Date*: 2006-01-31 | |||||||||||
Sponsor Name:Arpida AG | |||||||||||||
Full Title: Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Intravenous Linezolid in Complicated Skin and Skin Structure Infections | |||||||||||||
Medical condition: Complicated skin and skin structure infections are predominantly caused by the following Gram-positive pathogens: Staphylococcus aureus, including methicillin-resistant strains, beta hemolytic stre... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) GB (Completed) DE (Completed) LV (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001548-21 | Sponsor Protocol Number: ICLA-08-CSI1 | Start Date*: 2005-06-21 | |||||||||||
Sponsor Name:Arpida AG | |||||||||||||
Full Title: Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim versus Intravenous Linezolid in Complicated Skin and Skin Structure Infections | |||||||||||||
Medical condition: Complicated skin and skin structure infections are predominantly caused by the following Gram-positive pathogens: Staphylococcus aureus, including methicillin-resistant strains, beta hemolytic stre... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005090-26 | Sponsor Protocol Number: Kleb4V01 | Start Date*: 2021-06-21 | |||||||||||
Sponsor Name:LimmaTech Biologics AG | |||||||||||||
Full Title: Safety and immunogenicity of a Klebsiella pneumoniae tetravalent bioconjugate vaccine (Kleb4V) administered to healthy adults: A FTIH phase I/II randomized and controlled study. | |||||||||||||
Medical condition: Klebsiella pneumoniae (K. pneumoniae), a gram negative Enterobacteriaceae, is an opportunistic pathogen leading to hospital- and community-acquired infections (urinary tract infections, pneumonia a... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004108-16 | Sponsor Protocol Number: HOFATA_v3.0 | Start Date*: 2022-04-21 |
Sponsor Name:Medical University Vienna | ||
Full Title: Host factors predicting target site concentration of antibiotics in critically ill patients: An explorative pharmacokinetic biomarker study | ||
Medical condition: All patients given standard of care intravenous therapy of the studied antibiotics will be screened against the inclusion criteria. Two groups are included: Group A (septic patients with organ dysf... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-005161-31 | Sponsor Protocol Number: AT-201 | Start Date*: 2017-07-04 | ||||||||||||||||
Sponsor Name:Allecra Therapeutics SAS | ||||||||||||||||||
Full Title: Randomized, Double-Blind, Multi-Center Study of Cefepime/AAI101 in Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis | ||||||||||||||||||
Medical condition: Complicated urinary tract infections including acute pyelonephritis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-004646-33 | Sponsor Protocol Number: DORINOS3008 | Start Date*: 2008-07-08 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Prospective, Randomized, Double-Blind, Double-Dummy, Multicenter Study to Assess the Safety and Efficacy of Doripenem Compared With Imipenem-Cilastatin in the Treatment of Subjects with Ventilato... | |||||||||||||
Medical condition: Ventilator-Associated Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) BE (Completed) PT (Prematurely Ended) DE (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001653-40 | Sponsor Protocol Number: 64041575RSV2003 | Start Date*: 2016-12-09 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered ALS-008176 Re... | |||||||||||||
Medical condition: Respiratory Syncytial Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) SE (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001276-56 | Sponsor Protocol Number: AIDA | Start Date*: 2014-07-11 |
Sponsor Name:North Bristol NHS - Southmead Hospital | ||
Full Title: A prospective, open label, randomised controlled clinical trial, with pharmacokinetic-pharmacodynamic validation, to compare antimicrobial treatment with oral minocycline plus rifampicin to treatme... | ||
Medical condition: Complicated Skin and Skin Structure infections caused by Methicillin Resistant Staphylococcus Aureus | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IT (Completed) GR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004868-35 | Sponsor Protocol Number: AT-301 | Start Date*: 2018-08-23 | ||||||||||||||||
Sponsor Name:Allecra Therapeutics SAS | ||||||||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Cefepime- AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Ur... | ||||||||||||||||||
Medical condition: Complicated urinary tract infections including acute pyelonephritis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: LT (Completed) LV (Completed) ES (Completed) BG (Completed) SK (Completed) PL (Completed) HU (Completed) HR (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
